drugset / Trial / NCT04327791
COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)
Phase 2/3
Completed
15 enrolled
Bassett Healthcare
Genentech, Inc. · collabViroclinics Biosciences B.V. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment group (oseltamivir and placebo).
Timeline
- Start
- 2020-04-03
- Primary completion
- 2024-07-03
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baloxavir | Unknown | 40 mg | Oral |
| Subject | Baloxavir | Unknown | 80 mg | Oral |